Scribe Therapeutics Prices Upsized $128.7M IPO at $15/Share, Adds Sanofi Placement
Tom Rudovsky · Reported by GlobeNewswire
More coverage: Healthcare
Sentiment
Positive
Importance
8
Price
--
Mkt Cap
--
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time
Summary
Scribe Therapeutics priced its upsized IPO at $15.00 per share, the high end of the range, raising $128.7 million from 8.58 million shares. Sanofi is buying 500,000 shares in a concurrent private placement at the same price, adding $7.5 million. The stock begins trading July 24 on Nasdaq under 'SCTX,' and the offering is expected to close on July 27. The upsizing and high-end pricing signal robust institutional interest and strategic partner confidence for the clinical-stage CRISPR biotech advancing a lead candidate for cardiometabolic disease.
This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.
Price Chart
SCTX - Latest Insights
SCTX
Nov 12, 2026, 4:20 PM EST
Price at Filing:
$16.99
Real-time Price:
$12.00
Change:
-$4.99 (-29%)
Market Cap:
$228.576M
SCTX
Sep 02, 2026, 4:11 PM EDT
Price at Filing:
$30.90
Real-time Price:
$12.00
Change:
-$18.90 (-61%)
Market Cap:
$228.576M
SCTX
Sep 02, 2026, 4:08 PM EDT
Price at Filing:
$30.90
Real-time Price:
$12.00
Change:
-$18.90 (-61%)
Market Cap:
$228.576M
SCTX
Jul 30, 2026, 9:30 PM EDT
Price at Filing:
$22.46
Real-time Price:
$12.00
Change:
-$10.46 (-47%)
Market Cap:
$228.576M
SCTX
Jul 30, 2026, 4:39 PM EDT
Price at Filing:
$23.00
Real-time Price:
$12.00
Change:
-$11.00 (-48%)
Market Cap:
$228.576M